Bladder Cancer & VI-RADS
- Most bladder cancer is urothelial carcinoma, and the single question that changes everything is: has the tumor invaded the muscle layer (detrusor) of the bladder wall or not?
- VI-RADS (Vesical Imaging-Reporting and Data System) is an MRI scoring system, 1 to 5, that estimates the likelihood of muscle invasion before surgery: a lesion under 1 cm with an intact muscle line is VI-RADS 1, an interrupted muscle line is VI-RADS 4, and tumor out into the perivesical fat is VI-RADS 5.
- It reads three sequences (T2W, DWI, DCE) and, when T2W and DWI disagree, DWI wins; if DWI is unusable, DCE takes over.
- CT urography is still the tool for the upper tracts, where its pooled sensitivity for urothelial tumor in hematuria is about 96% and specificity about 99%.
- The classic trap: scan before the urologist's resection churns up the wall, or you'll be staring at inflammation pretending to be tumor.
Picture the bladder as a water balloon with a surprisingly fancy wall. The inside lining is a slick, stretchy layer called the urothelium, and that's where almost all bladder cancers start, growing inward into the urine like a little underwater shrub. The whole drama of bladder cancer comes down to one boundary: the muscle layer just underneath. Stay above it, and the urologist can often shave the tumor out through a scope. Break through it, and the conversation changes to removing the whole bladder. So the entire imaging job is really one yes-or-no question wearing a lab coat.
What you're actually dealing with
The overwhelming majority of bladder cancers are urothelial carcinoma (you'll also see the old name transitional cell carcinoma), the same cell type that lines the renal pelvis and ureters, which is why these tumors love to show up in more than one spot along the tract (the whole-tract story is on the urothelial cancer page). They classically present as painless visible blood in the urine, the kind that makes a patient and a urologist equally nervous.
The make-or-break distinction is non-muscle-invasive bladder cancer (NMIBC), confined to the lining and the loose layer beneath it, versus muscle-invasive bladder cancer (MIBC), which has breached the detrusor. NMIBC is usually managed with scope-based resection and bladder instillations; MIBC pushes management toward removing the bladder and chemotherapy. Same disease, completely different life.
The bladder wall on MRI is the key to everything that follows, so here it is from the inside out: the urothelium and the loose lamina propria beneath it (together the "inner layer," which can look thick and bright when it is edematous or inflamed), then the muscularis propria or detrusor, which shows as a crisp low-signal (dark) line on T2-weighted images, and outside that the bright perivesical fat. Bladder cancers often grow on a little stalk with a non-cancerous core, and that stalk is a reassuring sign: a tumor that still has one is hanging off the wall rather than burrowing into it.
Findings by modality
CT and CT urography
CT is how most bladder tumors are found: an enhancing soft-tissue mass or focal wall thickening projecting into the lumen, best seen when the bladder is distended, and a filling defect in the contrast-filled bladder on the excretory phase of a CT urogram. CTU also does the job MRI does not, checking the renal pelves and ureters for synchronous tumors. But CT is genuinely bad at the one thing that matters most for treatment: reading the depth of invasion through those wafer-thin wall layers. It sees perivesical fat stranding and frank extravesical mass, and it sees nodes and distant disease, but "in the muscle or not" is beyond it.
MRI (multiparametric)
This is where VI-RADS lives. The scan uses three views of the same tumor:
| Sequence | What it's good at | The headline |
|---|---|---|
| T2-weighted (T2W) | Anatomy of the wall layers | Is the dark muscularis propria line continuous under the tumor, or interrupted? Is there a stalk or a thickened bright inner layer? |
| Diffusion (DWI/ADC) | How tightly packed the tumor cells are | Tumor is bright on high-b-value DWI and dark on the ADC map; does that signal stop at the muscle line or extend into it? |
| Dynamic contrast-enhanced (DCE) | Early blood flow into tumor | Tumor and the inner layer enhance early; the muscle enhances later. Does early enhancement stay above the muscle or push into it? |
The trick is that VI-RADS basically asks one question three times: does that bright, busy tumor signal respect the dark muscle line, or does it bulldoze through it? If diffusion is doing the heavy lifting and the muscle stays crisp and dark, the score stays low.
Ultrasound
Ultrasound shows a bladder tumor as a fixed, echogenic, often vascular mass projecting from the wall into the anechoic urine, and it will happily pick up a large one in a patient scanned for hematuria. It cannot stage the wall reliably and it cannot see the upper tracts well, so it is a finder, not a decider.
Cystoscopy (the non-imaging test)
The urologist's camera is the reference standard for finding bladder tumors and remains part of every hematuria workup. Imaging complements it in two directions: CTU for the parts the scope cannot reach, and MRI for the depth the scope cannot see.
The numbers
| What | Threshold / value | Why it matters |
|---|---|---|
| VI-RADS 1 versus 2 size cut | <1 cm (category 1) versus >1 cm (category 2), with the muscularis line continuous in both | Small lesions with an intact muscle line are the lowest-risk group |
| VI-RADS 4 defining finding | Interruption of the low-signal muscularis propria line on T2W; focal extension of early enhancement (DCE) or of tumor (DWI) into the muscularis propria | Muscle invasion likely: the report that changes the operation |
| VI-RADS 5 defining finding | Tumor extends through the entire bladder wall into perivesical fat on T2W, DCE, and DWI | Invasion of muscle and beyond the bladder very likely |
| Dominant-sequence rule | If T2W and DWI disagree, DWI is dominant; if DWI is suboptimal, DCE becomes dominant | Settles the final category when the sequences argue |
| CTU for upper tract urothelial carcinoma in hematuria | Pooled sensitivity 96% (95% CI 88–100%); pooled specificity 99% (95% CI 98–100%) | Why CTU, not MRI, clears the renal pelves and ureters |
How good is the test
For the upper tracts, CT urography in patients presenting with hematuria has a pooled sensitivity of 96% (95% CI 88–100%) and specificity of 99% (95% CI 98–100%) for urothelial carcinoma, which is why it is the tool for clearing the renal pelves and ureters.
For VI-RADS itself, meta-analyses of its accuracy for predicting muscle invasion exist, but I'm not quoting one here. The honest summary is that a well-performed, pre-resection multiparametric MRI read with VI-RADS is a reliable predictor of muscle invasion, that it is a probability estimate rather than a tissue diagnosis, and that the pathologist still has the final word.
Classification: VI-RADS, abbreviated
VI-RADS 2018 (Panebianco et al.), abbreviated. The full table with the T2W, DWI, and DCE criteria per category, the dominant-sequence rule, and worked examples is on the VI-RADS classification page.
| Category | Core finding | Muscle invasion |
|---|---|---|
| 1 | Lesion <1 cm with a continuous low-signal muscularis propria line on T2W (with or without a stalk or thickened inner layer); line intact on DCE and DWI | Highly unlikely |
| 2 | Lesion >1 cm with a continuous low-signal muscularis line: papillary tumor with a stalk, or sessile tumor with a thickened high-signal inner layer; line intact on DCE and DWI | Unlikely |
| 3 | No stalk (papillary) or no high-signal thickened inner layer (sessile), but the low-signal muscularis line is still continuous | Equivocal |
| 4 | Interruption of the low-signal muscularis propria line on T2W; focal extension of early enhancement (DCE) or of tumor (DWI) into the muscularis propria | Likely |
| 5 | Tumor extends through the entire bladder wall into perivesical fat on T2W, DCE, and DWI | Very likely, and beyond the bladder |
Roughly: VI-RADS 1–2 means the dark muscle line looks intact and there is a reassuring stalk or inner layer; VI-RADS 3 is the genuinely on-the-fence middle child, where the reassuring features are gone but the muscle line still holds; and VI-RADS 4–5 means invasion is likely, with 5 implying tumor beyond the wall. When the sequences disagree, DWI is the tiebreaker, and if DWI is wrecked by artifact, DCE steps in. Think of it as a confidence dial, not a diagnosis carved in stone.
A higher VI-RADS score means a higher likelihood of muscle invasion. It is a probability estimate, not a tissue diagnosis, and it says nothing about lymph nodes or distant spread.
What could it be instead
| Mimic | Looks similar because | Tell them apart by |
|---|---|---|
| Blood clot | Soft-tissue filling defect in the bladder on CT or MRI | No enhancement, no restricted diffusion, mobile and dependent, changes between studies |
| Post-resection (TURBT) change | Focal wall thickening and edema that enhances and can restrict diffusion | The history and the site of resection; ideally avoid by scanning before resection |
| Cystitis (infective, radiation, BCG) | Diffuse wall thickening with enhancement | Circumferential and smooth rather than focal and mass-like; the clinical setting |
| Trabeculated wall from outlet obstruction | Irregular, thick wall with pseudo-masses between bands of hypertrophied muscle | Diffuse, symmetric, and paired with an enlarged prostate or a distended bladder (see BPH) |
| Median lobe of the prostate | A smooth "mass" at the bladder base | Continuous with the prostate on sagittal images; covered by intact urothelium |
| Urachal tumor | Mass at the dome of the bladder | Centered on the midline anterior dome and extending toward the umbilicus, often with calcification |
| Direct invasion from a neighbour (colon, cervix, prostate) | Focal wall mass with loss of the muscle line | The bulk of the tumor is outside the bladder and the primary is visible |
| Underdistended bladder | Folded, thick wall that looks like a tumor base | Rescan with the bladder comfortably full and the folds disappear |
Biopsy first, MRI second = a mess. A transurethral resection of bladder tumor (TURBT) tears up the wall, leaving inflammation and edema that mimic invading tumor on T2W and enhance like the real thing. Ideally the MRI is done before the scope, or after enough time for the wall to settle. Scan a freshly resected bladder and you'll over-call invasion all day.
Two more honest limitations. First, VI-RADS scores local muscle invasion only: it says nothing about lymph nodes or distant spread, so it is not full cancer staging, and the patient still needs the bigger picture. Second, the bladder must be comfortably but not painfully full: a collapsed bladder crumples the wall into folds that fake a thickened, suspicious base, while a bursting one is its own kind of misery.
Get the bladder moderately distended and image before instrumentation. A clean, well-timed VI-RADS read genuinely helps the urologist decide between "shave it out" and "this needs a bigger operation," which is the whole point of doing the MRI in the first place.
Reporting
- Each lesion: location by wall (dome, anterior, posterior, lateral, trigone, and its relation to the ureteric orifices and the bladder neck), size, morphology (papillary with a stalk, or sessile).
- The wall beneath it, sequence by sequence: is the low-signal muscularis line continuous on T2W; does DWI show tumor stopping at or extending into the muscle; does DCE early enhancement stay above or push into the muscle.
- The VI-RADS category, with a note of which sequence was dominant if they disagreed, and whether any sequence was suboptimal.
- Beyond the wall: perivesical fat, adjacent organs, pelvic and retroperitoneal nodes, bone on the included images.
- The upper tracts: whether CTU has been done or is needed, and any hydronephrosis from a tumor at the ureteric orifice.
- Technical: bladder distension, artifacts, and whether the study was before or after resection.
So when you boil it all down, bladder cancer imaging is one relentless question asked three different ways: is the muscle still in one piece? Keep that dark detrusor line in mind, time your scan around the resection, remember that DWI is the tiebreaker, and VI-RADS stops feeling like alphabet soup and starts feeling like a straight answer.
References
- Panebianco V, Narumi Y, Altun E, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol 2018;74(3):294–306. Used for: the VI-RADS 1 to 5 category definitions (including the <1 cm and >1 cm size cut, the stalk and thickened inner layer criteria, the interrupted muscularis line, and extension into perivesical fat) and the dominant-sequence rule (DWI over T2W; DCE when DWI is suboptimal) in Key Points, "The numbers", the Measurement chip, and "Classification: VI-RADS, abbreviated".
- Chlapoutakis K, Theocharopoulos N, Yarmenitis S, Damilakis J. Performance of computed tomographic urography in diagnosis of upper urinary tract urothelial carcinoma, in patients presenting with hematuria: Systematic review and meta-analysis. Eur J Radiol 2010;73(2):334–338. Used for: the pooled sensitivity of 96% (95% CI 88–100%) and specificity of 99% (95% CI 98–100%) of CT urography for upper tract urothelial carcinoma in hematuria, in Key Points, "The numbers", and "How good is the test".
Sign in to take the quiz and track your progress